Vertex Pharma (VRTX) r&d spend was $3.9B in FY2025 (+8% YoY). The tables below show the complete quarterly and annual r&d spend history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual R&D Spend
Fiscal Year
R&D Spend
YoY
2025
$3.9B
+8%
2024
$3.6B
+15%
2023
$3.2B
+25%
2022
$2.5B
+31%
2021
$1.9B
+18%
2020
$1.6B
-6%
2019
$1.8B
+24%
2018
$1.4B
+7%
2017
$1.3B
+26%
2016
$1.0B
+5%
2015
$996M
+16%
2014
$856M
-3%
2013
$882M
+15%
2012
$766M
+8%
2011
$708M
+11%
2010
$637M
+16%
2009
$550M
+6%
2008
$517M
Recent Quarterly R&D Spend
Quarter
R&D Spend
Q1 2026
$962M
Q4 2025
$974M
Q3 2025
$978M
Q2 2025
$978M
Q1 2025
$980M
Q4 2024
$999M
Q3 2024
$876M
Q2 2024
$967M
Q1 2024
$789M
Q4 2023
$825M
Q3 2023
$810M
Q2 2023
$786M
Source: VRTX on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.